Optimization of Tumor Radiotherapy With Modulators of Cell Metabolism: Toward Clinical Applications

Seminars in Radiation Oncology

Volumn 23, Issue 4, 2013, Pages 262-272

  Danhier, Pierre ^a   De Saedeleer, Christophe J ^a   Karroum, Oussama ^a   De Preter, Géraldine ^a   Porporato, Paolo E ^a   Jordan, Bénédicte F ^a   Gallez, Bernard ^a   Sonveaux, Pierre ^a,b  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINONICOTINAMIDE; ARSENIC TRIOXIDE; CYTOCHROME C OXIDASE; FLUORODEOXYGLUCOSE F 18; LACTIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NITRIC OXIDE DONOR; PACLITAXEL; PENTOSE PHOSPHATE; REACTIVE OXYGEN METABOLITE; SORAFENIB;

AEROBIC METABOLISM; ANAEROBIC GLYCOLYSIS; ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CELL KILLING; CELL METABOLISM; CELL PROLIFERATION; CITRIC ACID CYCLE; DNA DAMAGE; GLIOBLASTOMA; GLUCOSE INTAKE; GLUCOSE METABOLISM; HUMAN; HYPERTHERMIC THERAPY; IN VITRO STUDY; LOW ENERGY RADIATION; MITOCHONDRIAL RESPIRATION; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PENTOSE PHOSPHATE CYCLE; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RADIATION DOSE; RADIOSENSITIVITY; RESPIRATORY CHAIN; SOLID TUMOR; STROMA CELL; TISSUE PRESERVATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VASODILATATION;

ANIMALS; CELL HYPOXIA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCOSE; GLYCOLYSIS; HUMANS; LACTATES; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN; RADIATION-SENSITIZING AGENTS;

EID: 84883508982     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.05.008     Document Type: Article

References (130)

1. Rockwell S., Dobrucki I.T., Kim E.Y., et al. Hypoxia and radiation therapy: Past history, ongoing research, and future promise. Curr Mol Med 2009, 9:442-458.
2. Harada H. How can we overcome tumor hypoxia in radiation therapy?. J Radiat Res 2011, 52:545-556.
3. Jordan B.F., Sonveaux P. Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front Pharmacol 2012, 3:94.
4. Schwarz G. Ueber desensibilisierung gegen röntgen-und radiumstrahlen. Münchener Med Wochenschr 1909, 24:1-2.
5. Hall E.J., Giaccia A.J. Radiobiology for the Radiologist 2006, Lippincott Williams & Wilkins, Philadelphia, PA. 6th edition.
6. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11:393-410.
7. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26:638-648.
8. Dewhirst M.W., Cao Y., Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008, 8:425-437.
9. Dewhirst M.W. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009, 172:653-665.
10. Nehmeh S.A. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 70:235-242.
11. Cao Y., Li C.Y., Moeller B.J., et al. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 2005, 65:5498-5505.
12. Lanzen J. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res 2006, 66:2219-2223.
13. Bennewith K.L., Raleigh J.A., Durand R.E. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res 2002, 62:6827-6830.
14. *-weighted GRE signal within tumors. NMR Biomed 2006, 19:69-76.
15. Kavanagh B.D., Coffey B.E., Needham D., et al. The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment. Br J Cancer 1993, 67:734-741.
16. Dewhirst M.W. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl 1996, 27:S247-S251.
17. Patan S., Munn L.L., Jain R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis. Microvasc Res 1996, 51:260-272.
18. Zakrzewicz A., Secomb T.W., Pries A.R. Angioadaptation: Keeping the vascular system in shape. News Physiol Sci 2002, 17:197-201.
19. Sonveaux P. Provascular strategy: Targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol 2008, 86:300-313.
20. Vaupel P., Hockel M. Oxygenation of human tumors. Blood Perfusion and Microenvironment of Human Tumors 1998, 63-72. Springer-Verlag, Berlin, Germany. M. Molls, P. Vaupel (Eds.).
21. Isa A.Y., Ward T.H., West C.M., et al. Hypoxia in head and neck cancer. Br J Radiol 2006, 79:791-798.
22. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 52:769-778.
23. Hoskin P., Rojas A., Saunders M. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: Mature results of a phase II nonrandomized study. Int J Radiat Oncol Biol Phys 2009, 73:1425-1431.
24. Janssens G.O., Rademakers S.E., Terhaard C.H., et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 2012, 30:1777-1783.
25. Peters L., Rischin D. Elusive goal of targeting tumor hypoxia for therapeutic gain. J Clin Oncol 2012, 30:1741-1743.
26. Sonveaux P., Lobysheva I.I., Feron O., et al. Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery. Physiology 2007, 22:97-112.
27. Hoff C.M. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol 2012, 51:419-432.
28. Segers J., Crokart N., Danhier P., et al. Use of xanthinol nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors. Int J Cancer 2010, 126:583-588.
29. Sonveaux P., Kaz A.M., Snyder S.A., et al. Oxygen regulation of tumor perfusion by S-nitrosohemoglobin reveals a pressor activity of nitric oxide. Circ Res 2005, 96:1119-1126.
30. Frerart F., Sonveaux P., Rath G., et al. The acidic tumor microenvironment promotes the reconversion of nitrite into nitric oxide: Towards a new and safe radiosensitizing strategy. Clin Cancer Res 2008, 14:2768-2774.
31. Sonveaux P., Dessy C., Martinive P., et al. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: Implications for cancer treatment. Cancer Res 2004, 64:3209-3214.
32. Martinive P., De Wever J., Bouzin C., et al. Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 2006, 5:1620-1627.
33. Sonveaux P., Dessy C., Brouet A., et al. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J 2002, 16:1979-1981.
34. Crokart N., Jordan B.F., Baudelet C., et al. Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys 2005, 63:901-910.
35. Vaupel P. Tumor blood flow. Blood Perfusion and Microenvironment of Human Tumors 1998, 41-46. Springer-Verlag, Berlin, Germany. M. Molls, P. Vaupel (Eds.).
36. Sonveaux P., Jordan B.F., Gallez B., et al. Nitric oxide delivery to cancer: Why and how?. Eur J Cancer 2009, 45:1352-1369.
37. Chaplin D.J., Horsman M.R., Trotter M.J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst 1990, 82:672-676.
38. Kelleher D.K., Vaupel P.W. Possible mechanisms involved in tumor radiosensitization following nicotinamide administration. Radiother Oncol 1994, 32:47-53.
39. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105:1045-1047.
40. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001, 7:987-989.
41. Goel S., Duda D.G., Xu L., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
42. Secomb T.W., Hsu R., Ong E.T., et al. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995, 34:313-316.
43. Secomb T.W., Hsu R., Dewhirst M.W. Synergistic effects of hyperoxic gas breathing and reduced oxygen consumption on tumor oxygenation: A theoretical model. Int J Radiat Oncol Biol Phys 2004, 59:572-578.
44. Dewhirst M.W., Navia I.C., Brizel D.M., et al. Multiple etiologies of tumor hypoxia require multifaceted solutions. Clin Cancer Res 2007, 13:375-377.
45. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
46. Sonveaux P., Vegran F., Schroeder T., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118:3930-3942.
47. Porporato P.E., Dadhich R.K., Dhup S., et al. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front Pharmacol 2011, 2:49.
48. Dhup S., Dadhich R.K., Porporato P.E., et al. Multiple biological activities of lactic acid in cancer: Influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des 2012, 18:1319-1330.
49. Vaupel P., Mayer A. Availability, not respiratory capacity governs oxygen consumption of solid tumors. Int J Biochem Cell Biol 2012, 44:1477-1481.
50. Frezza C., Pollard P.J., Gottlieb E. Inborn and acquired metabolic defects in cancer. J Mol Med 2011, 89:213-220.
51. Jordan B.F., Gregoire V., Demeure R.J., et al. Insulin increases the sensitivity of tumors to irradiation: Involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002, 62:3555-3561.
52. Crokart N., Radermacher K., Jordan B.F., et al. Tumor radiosensitization by antiinflammatory drugs: Evidence for a new mechanism involving the oxygen effect. Cancer Res 2005, 65:7911-7916.
53. Ansiaux R., Baudelet C., Jordan B.F., et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 2006, 66:9698-9704.
54. Ansiaux R., DeWever J., Gregoire V., et al. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res 2009, 172:584-591.
55. Diepart C., Karroum O., Magat J., et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res 2012, 72:482-490.
56. Deorukhkar A., Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 2010, 80:1904-1914.
57. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899.
58. Diaz-Ruiz R., Rigoulet M., Devin A. The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta 2011, 1807:568-576.
59. Lin X., Zhang F., Bradbury C.M., et al. 2-deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 2003, 63:3413-3417.
60. Coleman M.C., Asbury C.R., Daniels D., et al. 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 2008, 44:322-331.
61. Matsudaira H., Furuno I., Otsuka H. Possible requirement of adenosine triphosphate for the rejoining of x-ray-induced breaks in the DNA of Ehrlich ascites-tumour cells. Int J Radiat Biol Relat Stud Phys Chem Med 1970, 17:339-347.
62. Jain V.K., Kalia V.K., Sharma R., et al. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 1985, 11:943-950.
63. Dwarkanath B.S., Zolzer F., Chandana S., et al. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 2001, 50:1051-1061.
64. Sinthupibulyakit C., Grimes K.R., Domann F.E., et al. p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose. Int J Oncol 2009, 35:609-615.
65. Mohanti B.K., Rath G.K., Anantha N., et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996, 35:103-111.
66. Singh D., Banerji A.K., Dwarakanath B.S., et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005, 181:507-514.
67. Dwarakanath B.S., Singh D., Banerji A.K., et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: Present status and future prospects. J Cancer Res Ther 2009, 5(suppl 1):S21-S26.
68. Varshney R., Dwarakanath B., Jain V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int J Radiat Biol 2005, 81:397-408.
69. Jordan B.F., Beghein N., Crokart N., et al. Preclinical safety and antitumor efficacy of insulin combined with irradiation. Radiother Oncol 2006, 81:112-117.
70. Biaglow J.E., Lavik P.S., Ferencz N. Modification of radiation response through glucose-controlled respiration. Radiat Res 1969, 39:623-633.
71. Snyder S.A., Lanzen J.L., Braun R.D., et al. Simultaneous administration of glucose and hyperoxic gas achieves greater improvement in tumor oxygenation than hyperoxic gas alone. Int J Radiat Oncol Biol Phys 2001, 51:494-506.
72. van den Berg A.P., van den Berg-Blok A.E., Kal H.B., et al. A moderate elevation of blood glucose level increases the effectiveness of thermoradiotherapy in a rat tumor model II. Improved tumor control at clinically achievable temperatures. Int J Radiat Oncol Biol Phys 2001, 50:793-801.
73. Nagata K., Murata T., Shiga T., et al. Enhancement of thermoradiotherapy by glucose administration for superficial malignant tumours. Int J Hyperthermia 1998, 14:157-167.
74. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
75. Semenza G.L. HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010, 20:51-56.
76. Christofk H.R., Vander Heiden M.G., Harris M.H., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
77. David C.J., Chen M., Assanah M., et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
78. Dang C.V. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010, 70:859-862.
79. Walenta S., Snyder S., Haroon Z.A., et al. Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 2001, 51:840-848.
80. Tanaka M., Nakamura F., Mizokawa S., et al. Role of lactate in the brain energy metabolism: Revealed by bioradiography. Neurosci Res 2004, 48:13-20.
81. Leite T.C., Coelho R.G., Da Silva D., et al. Lactate downregulates the glycolytic enzymes hexokinase and phosphofructokinase in diverse tissues from mice. FEBS Lett 2011, 585:92-98.
82. Bonuccelli G., Tsirigos A., Whitaker-Menezes D., et al. Ketones and lactate fuel tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514.
83. Martinez-Outschoorn U.E., Pavlides S., Howell A., et al. Stromal-epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol 2011, 43:1045-1051.
84. Halestrap A.P., Wilson M.C. The monocarboxylate transporter family-role and regulation. IUBMB Life 2012, 64:109-119.
85. Dimmer K.S., Friedrich B., Lang F., et al. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000, 350(Pt 1):219-227.
86. Ullah M.S., Davies A.J., Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006, 281:9030-9037.
87. Whitaker-Menezes D., Martinez-Outschoorn U.E., Lin Z., et al. Evidence for a stromal-epithelial lactate shuttle in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011, 10:1772-1783.
88. Rademakers S.E., Lok J., van der Kogel A.J., et al. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011, 11:167.
89. Miranda-Goncalves V., Honavar M., Pinheiro C., et al. Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets. Neuro Oncol 2013, 15:177-188.
90. Vegran F., Boidot R., Michiels C., et al. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 2011, 71:2550-2560.
91. Sonveaux P., Copetti T., De Saedeleer C.J., et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One. e33418 2012, 7.
92. De Saedeleer C.J., Copetti T., Porporato P.E., et al. Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. PLoS One. e46571 2012, 7.
93. Yaromina A., Meyer S., Fabian C., et al. Effects of three modifiers of glycolysis on ATP, lactate, hypoxia, and growth in human tumor cell lines in vivo. Strahlenther Onkol 2012, 188:431-437.
94. Lee Y., Morrison B.M., Li Y., et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012, 487:443-448.
95. Fishbein W.N. Lactate transporter defect: A new disease of muscle. Science 1986, 234:1254-1256.
96. Gallagher S.M., Castorino J.J., Wang D., et al. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007, 67:4182-4189.
97. Howard-Flanders P. Effect of nitric oxide on the radiosensitivity of bacteria. Nature 1957, 180:1191-1192.
98. Clementi E., Brown G.C., Foxwell N., et al. On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc Natl Acad Sci U S A 1999, 96:1559-1562.
99. Dranka B.P., Hill B.G., Darley-Usmar V.M. Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species. Free Radic Biol Med 2010, 48:905-914.
100. Mitchell J.B., Wink D.A., DeGraff W., et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 1993, 53:5845-5848.
101. Griffin R.J., Makepeace C.M., Hur W.J., et al. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J Radiat Oncol Biol Phys 1996, 36:377-383.
102. Jordan B.F., Sonveaux P., Feron O., et al. Nitric oxide as a radiosensitizer: Evidence for an intrinsic role in addition to its effect on oxygen delivery and consumption. Int J Cancer 2004, 109:768-773.
103. De Ridder M., Verellen D., Verovski V., et al. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008, 19:164-169.
104. Jordan B.F., Misson P., Demeure R., et al. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000, 48:565-570.
105. Thews O., Kelleher D.K., Vaupel P. No improvement in perfusion and oxygenation of experimental tumors upon application of vasodilator drugs. Int J Oncol 2001, 19:1243-1247.
106. Jordan B.F., Beghein N., Aubry M., et al. Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors. Int J Cancer 2003, 103:138-141.
107. Jordan B.F., Peeterbroeck J., Karroum O., et al. Captopril and S-nitrosocaptopril as potent radiosensitizers: Comparative study and underlying mechanisms. Cancer Lett 2010, 293:213-219.
108. Moya M.P., Gow A.J., Califf R.M., et al. Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn. Lancet 2002, 360:141-143.
109. Holland M.A., Kozlowski L.M. Clinical features and management of cyanide poisoning. Clin Pharm 1986, 5:737-741.
110. de Bono J.S., Dalgleish A.G., Carmichael J., et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000, 6:397-405.
111. Jiang H., De Ridder M., Verovski V.N., et al. Activated macrophages as a novel determinant of tumor cell radioresponse: The role of nitric oxide-mediated inhibition of cellular respiration and oxygen sparing. Int J Radiat Oncol Biol Phys 2010, 76:1520-1527.
112. Dhillon A.S., Hagan S., Rath O., et al. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
113. Cohen-Jonathan E., Evans S.M., Koch C.J., et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 2001, 61:2289-2293.
114. Solomon B., Binns D., Roselt P., et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 2005, 4:1417-1422.
115. Biaglow J.E., Cerniglia G., Tuttle S., et al. Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis. Biochem Biophys Res Commun 1997, 235:739-742.
116. Telang S., Lane A.N., Nelson K.K., et al. The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer 2007, 6:77.
117. Karroum O., Kengen J., Danhier P., et al. Tumor reoxygenation following administration of mitogen-activated protein kinase inhibitors: A rationale for combination with radiation therapy. Radiother Oncol 2012, 105:64-71.
118. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
119. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
120. Milas L., Hunter N., Mason K.A., et al. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol 1995, 34:409-412.
121. Milas L. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995, 55:3564-3568.
122. Danhier F., Danhier P., Magotteaux N., et al. Electron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxel. PLoS One. e40772 2012, 7.
123. Zhu J., Chen Z., Lallemand-Breitenbach V., et al. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002, 2:705-713.
124. Pelicano H., Feng L., Zhou Y., et al. Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003, 278:37832-37839.
125. Dewhirst M.W., Secomb T.W., Ong E.T., et al. Determination of local oxygen consumption rates in tumors. Cancer Res 1994, 54:3333-3336.
126. Diepart C., Jordan B.F., Gallez B. A new EPR oximetry protocol to estimate the tissue oxygen consumption in vivo. Radiat Res 2009, 172:220-225.
127. Diepart C., Magat J., Jordan B.F., et al. In vivo mapping of tumor oxygen consumption using (19)F MRI relaxometry. NMR Biomed 2011, 24:458-463.
128. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
129. Jordan B.F., Gallez B. Surrogate MR markers of response to chemo or radiotherapy in association with co-treatments: A retrospective analysis of multi-modal studies. Contrast Media Mol Imaging 2010, 5:323-332.
130. Horsman M.R., Mortensen L.S., Petersen J.B., et al. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012, 9:674-687.